Skip to main content

Conference Highlights ASH

Conference Highlights ASH

A Multicenter, Phase 4 Observational Study of Ofatumumab in Chronic Lymphocytic Leukemia: A European Research Initiative on CLL (ERIC) Study

Conference Highlights ASH

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia

Conference Highlights ASH

Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019

Wayne Kuznar

Conference Highlights ASH

American Society of Hypertension Highlights

Conference Highlights ASH

Chemoimmunotherapy with Fludarabine, Cyclophosphamide, and Rituximab versus Bendamustine and Rituximab in Previously Untreated and Physically Fit Patients with Advanced Chronic Lymphocytic Leukemia

Conference Highlights ASH

Chronic Lymphocytic Leukemia: A New Treatment Era is Born

Conference Highlights ASH

Combination Biologic Therapy Without Chemotherapy as Initial Treatment for Mantle-Cell Lymphoma: Multicenter Phase 2 Study of Lenalidomide Plus Rituximab

Conference Highlights ASH

DVT Prophylaxis: First Comparison of Catheter- Directed Thrombolysis versus Standard Care

Neil Canavan, Neil Canavan

Conference Highlights ASH

Favorable Data for Ruxolitinib and for a New JAK Inhibitor in Myelofibrosis

Neil Canavan, Neil Canavan

Conference Highlights ASH

Genetic Profiles Linked to Hematologic Outcomes

Caroline Helwick, Caroline Helwick

Page 1 of 4
Results 1 - 10 of 35